CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
复制标题
DOI：
10.1158/1078-0432.ccr-14-2551
复制
发表时间：
2015-03-15
期刊：
影响因子：
--
通讯作者：
Sparreboom A
中科院分区：
文献类型：
--
作者：
Pabla N;Sparreboom A
在2001年5月1日出版的《临床癌症研究》杂志上发表的一篇里程碑式的文章中，Lee和他的同事报告了最初的临床前研究，证明了BMS-247550（ixabelipone）对紫杉烷敏感和紫杉烷耐药癌症的抗癌活性。随后的临床试验确立了伊沙匹隆的临床疗效，导致其监管机构批准用于治疗耐药转移性或局部晚期乳腺癌。
In a landmark article published in the May 1, 2001, issue of Clinical Cancer Research, Lee and colleagues reported the original preclinical studies demonstrating anticancer activity of BMS-247550 (ixabelipone) against taxane-sensitive and taxane-resistant cancers. Subsequent clinical trials established clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers.